| 07/01/22 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 06/01/22 | Notification about results of final buy-back of shares | AQ |
| 30/12/21 | Notification about final share buy-back | AQ |
| 28/12/21 | Correction: Regarding results of a share buy-back offer | AQ |
| 28/12/21 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 01/01/2026 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 01/01/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 19/06/2021 | |
Janis Buks
CHM | Chairman | - | 01/09/2022 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 4/8/21 | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.19% | +2.67% | - | - | 148M | |
| -0.42% | +0.73% | +19.60% | +71.34% | 48.37B | |
| +1.12% | +1.41% | +54.88% | +122.68% | 39.88B | |
| -0.51% | -0.48% | -10.42% | +15.16% | 12.05B | |
| +1.53% | +3.36% | +15.56% | +79.98% | 11.77B | |
| +0.19% | 0.00% | +30.98% | +150.00% | 9.19B | |
| -1.20% | +2.48% | +23.60% | +44.26% | 7.87B | |
| +1.30% | +1.26% | +54.43% | -10.73% | 7.25B | |
| +1.78% | +8.75% | +25.24% | +218.46% | 7.1B | |
| +0.95% | -8.22% | -39.88% | +16.67% | 5.26B | |
| Average | +1.20% | +0.69% | +19.33% | +78.65% | 16.53B | |
| Weighted average by Cap. | +0.38% | +1.17% | +27.09% | +85.75% |
Employees
2,191
Sector
Pharmaceuticals
